JNJ - Johnson & Johnson
| Previous Close | 126.66 |
| Open | 126.88 |
| Bid | 126.75 x 100 |
| Ask | 127.44 x 100 |
| Day's Range | 125.78 - 127.30 |
| 52 Week Range | 122.15 - 148.32 |
| Volume | 7,501,870 |
| Avg. Volume | 8,031,553 |
| Market Cap | 340.239B |
| Beta | 0.59 |
| PE Ratio (TTM) | 267.57 |
| EPS (TTM) | 0.47 |
| Earnings Date | Jul 17, 2018 |
| Forward Dividend & Yield | 3.36 (2.57%) |
| Ex-Dividend Date | 2018-02-26 |
| 1y Target Est | 149.05 |
- Market Realist•13 hours ago
Johnson & Johnson’s Revenues Continued to Rise in 1Q18
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
- Market Realist•18 hours ago
Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
- Motley Fool•18 hours ago
Johnson & Johnson's Top-Line Growth Isn't What It Seems
The company’s double-digit growth comes with some caveats.
- Motley Fool•20 hours ago
Geron Corporation: The Clock Is Ticking
Geron's stock has been a magnet for short-sellers, but the long thesis remains intact.
- Market Realist•20 hours ago
Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
- Market Realist•21 hours ago
Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
- Reuters•yesterday
British businesses embrace profits with a purpose
Like many combat veterans, Steve Hammond struggled for years after returning to civilian life, battling physical injuries that made it difficult to find a job and left him contemplating suicide. Now the 61-year-old father of two is thriving as a team leader with Britain's Bravest Manufacturing Company (BBMC), one of a growing number of socially-minded companies providing jobs for people marginalised from the traditional workforce. "It gives people with a disability or mental health issues a purpose in life," Hammond, who was wounded in the Falklands War, told the Thomson Reuters Foundation.
- Motley Fool•2 days ago
3 Things You Should Know About Today's Top Entrepreneurs
A new wave of innovation will change several of America's most established industries. Here are three important takeaways for investors.
- Motley Fool•2 days ago
Johnson & Johnson's First-Quarter 2018 Earnings Review
We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.
- Barrons.com•3 days ago
[$$] Square, eBay, and the Future of Money
Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.
- InvestorPlace•4 days ago
4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings
After a spell of high volatility driven by uncertainty over global trade policy and the threat of rise in prices of essential commodities, Wall Street is looking for some respite in the upcoming earnings season. Given the positive trend, investing in blue-chip stocks that are likely to make the most of the earnings season seems judicious. This is because such stocks are positioned to report impressive earnings results as they mostly have a strong balance sheet and solid cash flow.
- Zacks•4 days ago
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
- Zacks•4 days ago
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
- Simply Wall St.•4 days ago
AbbVie And Other Great Pharma And Biotech Income Stocks
Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...
- Zacks•4 days ago
Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress
The Dow experienced a particularly volatile week as earnings results took center stage.
- CNBC•4 days ago
Johnson & Johnson is betting on vision care and expanding beyond contacts
J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.
- CNBC•4 days ago
Johnson & Johnson is betting on vision care and expanding beyond contacts
J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.
- TheStreet.com•4 days ago
P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI
issues were still top of mind to just about everyone as investors continued to drive the stock down as well. It's tough for some investors to find a positive view of the Seattle-based coffee house company. It's been trading sideways for close to three years, producing a 2% return over the last 12 months compared with 15% for the S&P and a somewhat pricey 21 times P/E multiple for a food and beverage company, all of which make an unappetizing menu choice for investors, never mind the company's moral and ethical dilemmas, says Stephen Guilfoyle.
- Zacks•5 days ago
Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.
- Motley Fool•5 days ago
3 Drugs That Are Moving the Needle at Johnson & Johnson
Johnson & Johnson owes a lot of its early success this year to rapidly growing sales of three key products.
- Barrons.com•5 days ago
After the Bell: Dow Drops 38 Points Because…IBM
The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.
- CNBC•6 days ago
Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'
"I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.
- Reuters•6 days ago
Kentucky accuses J&J of contributing to opioid epidemic
Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction. The lawsuit by Kentucky Attorney General Andy Beshear was his fifth to date seeking to hold a drug manufacturer or distributor responsible for its role in the national opioid epidemic.
- MarketWatch•6 days ago
IBM and J&J stocks cut 100 points from Dow industrials in early trading
The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.
- CNBC Videos•6 days ago
Kentucky Governor Bevin: I'm not on board with JNJ opioid...
Kentucky Governor Matt Bevin discusses his state District Attorney suing Johnson & Johnson for contributing to the opioid epidemic through deceptive marketing.
